Endocyte Inc. (Nasdaq: ECYT) and Merck & Co. Inc. (NYSE: MRK) halted a late stage study of their ovarian cancer treatment vintafolide because it was not effective. Shares of Endocyte plummeted $10.62 to $6.76 while Merck stock dropped $1.52 to $58.10.
Endocyte And Merck Halt Study
May 02, 2014 at 08:16 AM EDT
